Search company, investor...
Terasaki Institute for Biomedical Innovation company logo

Terasaki Institute for Biomedical Innovation

terasaki.org

About Terasaki Institute for Biomedical Innovation

Terasaki Institute for Biomedical Innovation is a nonprofit organization that invents and fosters practical solutions that enhances the health of individuals. It is based in Los Angeles, California.

Headquarters Location

1018 Westwood Blvd

Los Angeles, California, 90024,

United States

Missing: Terasaki Institute for Biomedical Innovation's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Terasaki Institute for Biomedical Innovation's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Terasaki Institute for Biomedical Innovation Patents

Terasaki Institute for Biomedical Innovation has filed 3 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/10/2013

10/13/2020

Immunology, Clusters of differentiation, Immune system, HLA-B alleles, Monoclonal antibodies

Grant

Application Date

1/10/2013

Grant Date

10/13/2020

Title

Related Topics

Immunology, Clusters of differentiation, Immune system, HLA-B alleles, Monoclonal antibodies

Status

Grant

Latest Terasaki Institute for Biomedical Innovation News

Scientists Have Developed Contact Lenses That Help Prevent Dry Eye Syndrome

Mar 4, 2023

By Terasaki Institute for Biomedical InnovationMarch 4, 2023 Scientists have a contact lens prototype that is specially designed to prevent contact lens-induced dry eye. Credit: Terasaki Institute for Biomedical Innovation A team from the Terasaki Institute for Biomedical Innovation (TIBI) has created a groundbreaking contact lens prototype aimed at combating contact lens-induced dry eye (CLIDE). This innovative lens design helps to alleviate CLIDE by promoting tear flow through normal eye blinking. This development has the potential to ease the discomfort, vision problems, and inflammation risks faced by millions of contact lens wearers who suffer from CLIDE. Out of the 140 million people worldwide who wear contact lenses, between 30% to 50% experience CLIDE. CLIDE occurs due to an inadequate flow of tears from the outer surface of the contact lens to the inner surface, resulting in excessive tear evaporation and the associated symptoms of CLIDE. Current treatments for this condition include rewetting drops, gels, or lubricants, more frequent lens replacement, or changes in the lens material. There are also eyelid treatments, such as eyelid massage and warm compresses. In more severe cases, physical stimulation of the tear glands may be utilized, as well as the use of punctum plugs, devices inserted into tear ducts to block drainage. Efficacy varies among these treatments, however, there may also be potentially harmful accumulations of drugs in the body, and the non-user-friendly methods contribute to patient noncompliance. There have also been previous attempts to use contact lenses in treating dry eye syndrome, such as graphene-coated lenses designed to minimize moisture loss and self-moisturizing lenses stimulated with metallic electrodes. But these methods are costly and impractical and may compromise patient safety and comfort. The TIBI team’s approach uses a contact lens design that incorporates microchannels to facilitate tear flow movement and flow so that dry eye can be avoided. This flow can be achieved by pressure applied by normal eye blinking so that no external devices are needed. In fabricating their contact lens prototype, the team utilized a time-saving method – their lens mold was made from a silicone polymer mixture; this allowed for easy removal of the lens cast on it by gently bending the mold. Previous methods necessitated a twelve-hour soak in hot water to remove the lens. The approach resulted in high-quality, smooth microchannels, as well as lenses that could be thirty times thinner than previous lenses. A custom device was used to fabricate reservoirs at the ends of each microchannel for the inflow and outflow of liquids. Innovative techniques were also utilized when encapsulating the microchannels in a sandwich-like assembly under a capping lens layer. Initially, the preparation of the two lens surfaces for stronger bonding dehydrated the lenses, causing them to curl. This problem was solved by affixing the two lenses to holders using water-soluble glue. This served not only to enable a more uniform bonding of the lenses but protected them from damage as well. After rigorously testing their encapsulated microchannel lenses for stability and leakage, the lenses were subjected to a series of experiments using a device that the team designed to simulate a blinking eyelid. This device was integrated with the lens prototype to create artificial eyelid pressure on the lens to stimulate tear flow. After various experiments, a configuration that proved effective was microchannels with square cross-sections arrayed in a novel circular pattern on the lens surface; this was compatible with the function and curvature of the lens and allowed for optimum liquid flow. The team demonstrated a proof-of-concept validation of their lens’ ability to guide tear flow originating from the lens surface to the underside of the lens to combat dry eye syndrome. The team quantified these flows and established that the flows were driven by low-pressure levels like those from normal eye blinking. Further experiments could be devised to test these lenses on animal models and in patients. “The inventive methods that our team has employed bring a potential solution for millions of people,” said Ali Khademhosseini, TIBI’s Director and CEO. “It is the hope that we may extend our efforts to bring this solution to fruition.” Reference: “A Microfluidic Contact Lens to Address Contact Lens-Induced Dry Eye”  by Yangzhi Zhu, Rohollah Nasiri, Elham Davoodi, Shiming Zhang, Sourav Saha, Matthew Linn, Lu Jiang, Reihaneh Haghniaz, Martin C. Hartel, Vadim Jucaud, Mehmet R. Dokmeci, Anna Herland, Ehsan Toyserkani and Ali Khademhosseini, 23 December 2022, Small.

Terasaki Institute for Biomedical Innovation Frequently Asked Questions (FAQ)

  • Where is Terasaki Institute for Biomedical Innovation's headquarters?

    Terasaki Institute for Biomedical Innovation's headquarters is located at 1018 Westwood Blvd, Los Angeles.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.